

Press release

Contact:

Torben Jörgensen, President and CEO

Tel: +46 707 49 05 84, torben.jorgensen@biotage.com

Biotage AB

Kungsgatan 76

SE-753 18 Uppsala

Tel+46 18 56 59 00

www.biotage.com

Uppsala May 18, 2010

Biotage AB Acquires SPE Extraction and Evaporation Products from Caliper Life Sciences, Inc.

Biotage AB (STO: BIOT), a global leader in tools and technology for medicinal and analytical chemistry, and Caliper Life Sciences, Inc. (NASDAQ: CALP) today announces a transaction under which Biotage is acquiring extraction and evaporation product lines for Sample Preparation from Caliper.

Biotage is acquiring the RapidTrace® and TurboVap® product lines and all associated assets for a sum of USD 16,5m. These products had a turnover of USD 9,5m in 2009. Approximately eight employees of Caliper will be offered employment in Biotage. The business will be consolidated in the Biotage group as of May 25, 2010. The two product lines in summary:

RapidTrace SPE Workstation is a modular, highly scalable, automated Sample Prep high throughput Solid Phase Extraction (SPE) platform. A recent collaboration with Caliper resulted in the RapidTrace being fully compatible with all Biotage Isolute® SPE cartridges.

TurboVap Concentration Evaporator Workstations are microprocessor-controlled concentrators used for sample preparation that provide unattended, automated sample evaporation. The TurboVap product line is a logical add-on to the current Biotage evaporation products as a complement to the Biotage V-10™ solvent evaporation system.

"We are very pleased to see this transaction come through and we expect a significant improvement of our bottom line as this acquisition has a limited need for an extension of our present cost base. It is another important step in Biotage's strategic focus to expand further and deeper into the Sample Prep market where these products are an excellent complement to our existing product line. The extensive installed base of these products outside the pharma segment delivers new customer relationships into our new target markets of Food, Agricultural, Clinical, Forensics and Environmental. Our global sales outlet will take full advantage of these additions to our current portfolio. Caliper will continue to manufacture the products and we are in early stages of exploring further strategic collaboration opportunities." says Torben Jörgensen, Biotage AB President and CEO.

"RapidTrace and TurboVap are excellent products and have been very successful for Caliper. This divestiture will help us to focus on our new strategic direction of developing technologies enabling researchers in the life sciences to create life-saving and enhancing medicines and diagnostic tests. I believe that Biotage with its consumables offering will be able to further leverage this product portfolio and I also believe that Caliper and Biotage have great opportunities to take advantage of each other's core strengths in close collaboration." says Kevin Hrusovsky, Caliper Life Sciences President & CEO.

For more information regarding Biotage, email product_info@biotage.com or visit www.biotage.com.

The information in this press release is such that Biotage AB is required to disclose under the Swedish Securities Market Act and/or the Swedish Financial Instruments Trading Act. It was released for publication at 8.30am (CET) on May 18, 2010.

###

For further information, please contact: Torben Jörgensen, President and CEO, Tel: +46 707 49 05 84.

For further information regarding Caliper Life Sciences, contact: Kevin Hrusovsky, President & CEO, +01 508 497 2215

About Biotage

Biotage offers solutions, knowledge and experience in the areas of analytical chemistry and medicinal chemistry. The customers include the world's largest pharmaceutical and biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has subsidiaries in the US, UK and Japan. Biotage has 245 employees and had sales of 394.1 MSEK in 2009. Biotage is listed on the NASDAQ OMX Nordic Stockholm stock exchange. Website: www.biotage.com

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit www.caliperLS.com.